BioVie Inc

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=70939&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of BioVie Inc. (BIVI) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=70918&wire=1 or contact Joseph E. Levi, Esq.

BIVI LAWSUIT ALERT: Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

LOS ANGELES , March 13, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI). Class Period: August 5, 2021 – November 29, 2023 Lead Plaintiff Deadline: March 19, 2024 If you wish to serve as lead plaintiff of the BioVie lawsuit, you can submit your contact information at www.glancylaw.com/cases/BioVie-Inc/.

BIVI Investors Have Opportunity to Lead BioVie Inc. Securities Fraud Lawsuit

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=70714&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on BioVie Inc.(BIVI) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=70702&wire=1 or contact Joseph E. Levi, Esq.

Investors in BioVie Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights – BIVI

BioVie Inc. (BIVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=70651&wire=1 or contact Joseph E. Levi, Esq.

March 19, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against BIVI

PHILADELPHIA , March 12, 2024 /PRNewswire/ -- Berger Montague announces that a class action lawsuit was filed in the U.S. District Court for the District of Nevada on behalf of those who acquired BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI) securities. If you suffered losses as a result of your investment in BioVie (NASDAQ: BIVI) and would like to learn about a potential recovery, CLICK HERE.

BIOVIE INC. CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by March 19, 2024

NEW YORK , March 12, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioVie Inc. ("BioVie" or the "Company") (NASDAQ: BIVI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioVie investors who were adversely affected by alleged securities fraud between August 5, 2021 and November 29, 2023.

Class Action Filed Against BioVie Inc. (BIVI) - March 19, 2024 Deadline to Join - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / March 12, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=70551&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on BioVie Inc. (BIVI) should contact Levi & Korsinsky about pending Class Action - BIVI

NEW YORK, NY / ACCESSWIRE / March 11, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=70467&wire=1 or contact Joseph E. Levi, Esq.

BioVie Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - BIVI

NEW YORK, NY / ACCESSWIRE / March 11, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=70458&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI

BioVie Inc (NASDAQ:BIVI) told investors it has secured sufficient funds through a recently completed financing to progress its near-term clinical priority, developing its lead asset NE3107 for Parkinson's disease. It increased its cash balance by approximately $18.8 million after closing an equity financing round last week for gross proceeds of $21 million.

BioVie to kick off Phase 2b trial for lead asset in Parkinson's disease in late-summer

Recently completed financing provides sufficient funds for near-term Parkinson's Disease priority Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson's Disease being finalized with targeted launch late-summer 2024 Once-daily NE3107 formulation expected to be available early 2025 and will be used for Phase 3 trial in Alzheimer's Disease Phase 3 trial for BIV201 in preparation following FDA feedback with guidance on development path; program delayed pending partnership funding CARSON CITY, Nev., March 11, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that its recently completed funding round provides opportunity to further the Company's clinical priorities in Parkinson's Disease (PD), Alzheimer's Disease (AD), and ascites/liver disease.

BioVie Announces Pipeline Update and Near-Term Clinical Priorities

LOS ANGELES, CA / ACCESSWIRE / March 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

MARCH 19 FINAL DEADLINE: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , March 11, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioVie Inc.. Shareholders who purchased shares of BIVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

BioVie Inc. Class Action: The Gross Law Firm Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI

NEW YORK, NY / ACCESSWIRE / March 11, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=70306&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class Action - BIVI

LOS ANGELES, CA / ACCESSWIRE / March 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

MARCH 19 DEADLINE: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=70056&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – BIVI

NEW YORK, NY / ACCESSWIRE / March 8, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=69960&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIVI

LOS ANGELES, CA / ACCESSWIRE / March 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biovie-lawsuit-submission-form?prid=69827&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on BioVie Inc. (BIVI)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / March 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , March 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioVie Inc.. Shareholders who purchased shares of BIVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

News for BioVie Inc Stock (BIVI)